Resource Summary Report

Generated by NIF on Jul 29, 2026

Cyclin D1 Antibody

RRID:AB_2228523
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2922, RRID:AB_2228523

Antibody Information

URL: http://antibodyregistry.org/AB_2228523

Proper Citation: Cell Signaling Technology Cat# 2922, RRID:AB_2228523

Target Antigen: Cyclin D1

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10695719, AB_2228523.

Antibody Name: Cyclin D1 Antibody

Description: This unknown targets Cyclin D1

Target Organism: rat, mouse, human

Antibody ID: AB_2228523

Vendor: Cell Signaling Technology

Catalog Number: 2922

Record Creation Time: 20250820T030440+0000

Record Last Update: 20250820T151705+0000

Ratings and Alerts

- Used for western blot assay by the Human Islet Research Network community. Contact(s): Peng Wang, Andrew Stewart - Human Islets Research Network https://hirnetwork.org/

No alerts have been found for Cyclin D1 Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Liu F, et al. (2025) PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer. Oncogene, 44(33), 2997.

Guo Y, et al. (2025) Novel compounds with promising HuH-7 inhibitory activity as new cancer drug candidates: derivatives of N,N'-diphenylurea linked with 1,2,3-triazole. Journal of enzyme inhibition and medicinal chemistry, 40(1), 2585597.

Xie M, et al. (2025) Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer cell.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. bioRxiv : the preprint server for biology.

Puleo N, et al. (2025) Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer. Molecular cancer therapeutics, 24(4), 639.

Li X, et al. (2025) SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer. Journal of ovarian research, 18(1), 167.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. Cell reports, 43(5), 114134.

Dimitrov J, et al. (2024) Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells. Frontiers in immunology, 15, 1470620.

Jacob JR, et al. (2024) miRNA-194-3p represses NF-?B in gliomas to attenuate iPSC genes and proneural to mesenchymal transition. iScience, 27(1), 108650.

Lizardo MM, et al. (2024) Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(19), 4464.

Sun Y, et al. (2024) Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. Cancer cell, 42(8), 1386.

Restaino AC, et al. (2024) Tumor-associated genetic amplifications impact extracellular vesicle miRNA cargo and their recruitment of nerves in head and neck cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 38(13), e23803.

Yip HYK, et al. (2024) Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. NPJ precision oncology, 8(1), 20.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187(7), 1666.

Fu K, et al. (2024) Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell, 187(4), 882.

Shanmugam S, et al. (2023) Ethanol inhibition of undifferentiated rat neural progenitor cell replication can be prevented by chlorogenic acid via the NFATc4/CSE signaling pathway. Alcohol, clinical & experimental research, 47(8), 1530.

Kombiyil S, et al. (2023) In Vitro Anti-cancer Effect of Crataegus oxyacantha Berry Extract on Hormone Receptor Positive and Triple Negative Breast Cancers via Regulation of Canonical Wnt Signaling Pathway. Applied biochemistry and biotechnology, 195(4), 2687.

Flint AC, et al. (2023) Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(17), 3438.

Yang Y, et al. (2023) ?KG-driven RNA polymerase II transcription of cyclin D1 licenses malic enzyme 2 to promote cell-cycle progression. Cell reports, 42(7), 112770.